drugset / Trial / NCT03835637
Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects
Non-randomizedSequentialOpen-labelBasic science
Summary
This is a single centre, open-label, non-randomised study with up to 2 parts, assessing the safety, tolerability, PK and PD of single (Part A) and multiple (Part B; optional) doses of oral GR antagonist ORIC-101.
Timeline
- Start
- 2018-03-23
- Primary completion
- 2018-07-04
- Completion
- 2018-07-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ORIC-101 | Small molecule | — | Oral |
Indications
No indication recorded.